MedTrace Logo

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

NCT01389206 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 797

Last updated 2018-08-15

No results posted yet for this study

Summary

Knowledge Translation Program for the guidelines and evidence-based management of PAH patients

Conditions

Interventions

DRUG

observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi

observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi

Sponsors & Collaborators

  • Canadian Heart Research Centre

    collaborator OTHER

  • Actelion

    lead INDUSTRY

Principal Investigators

  • Vallerie McLaughlin, MD · University of Michigan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-01
Primary Completion
2018-04-10
Completion
2018-04-10
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01389206 on ClinicalTrials.gov